More seriously, the administration of granulocyte colony-stimulating factor (G-CSF) to counteract chemotherapy-induced neutropenia doubles the low risk of developing secondary leukemia following chemotherapy (Azim et al., 2011). The gene discussed is CSF3; the disease is Decreased total neutrophil count.